epz-5676 and Myelodysplastic-Syndromes

In the Myeloid session of the 30th Nagoya International Cancer Treatment Symposium, three speakers were invited. Prof. Clara Bloomfield emphasized the importance of genetic alterations for the prognostic stratification and treatment of acute myeloid leukemia (AML). Dr. Eytan Stein showed that there are promising anti-leukemia effects of IDH2 inhibitor, AG-221, and DOT1L inhibitor, EPZ-5676, based on early-phase clinical studies. Prof. Seishi Ogawa presented a review of the clonal dynamics of secondary myelodysplastic syndrome (MDS) derived from aplastic anemia (AA). From these presentations, we are confident that molecular analysis-based individualized therapies will be realized within a few years.

Topics: Aminopyridines; Anemia, Aplastic; Antineoplastic Agents; Benzimidazoles; Clonal Evolution; Genome, Human; Hematopoiesis; Histone-Lysine N-Methyltransferase; Humans; Immunosuppressive Agents; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Mutation; Myelodysplastic Syndromes; Triazines